![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » CORGENTECH REPORTS PAIN DRUG STUDY DATA
CORGENTECH REPORTS PAIN DRUG STUDY DATA
June 14, 2006
Corgentech has reported top-line clinical data from a Phase II trial of pain drug candidate 4975, which demonstrated pain reduction in patients after total knee replacement surgeries.
4975 is a new long-acting, non-opioid drug being developed for site-specific, moderate-to-severe pain. The drug showed pain reduction at all pre-specified time intervals in the study, with statistically significant pain relief on the first and the fourteenth days.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct